Endocrine

Subclinical hypothyroidism: when to treat

Clinical Overview and When to Suspect Subclinical Hypothyroidism

— Mild: TSH 4.5–9.9 mIU/L (≈90% of cases)

— Severe: TSH ≥10 mIU/L

— More common in women, whites, iodine-sufficient regions, autoimmune disease (T1DM, celiac, vitiligo), Down/Turner syndromes

— Chronic autoimmune thyroiditis (Hashimoto) — most common; TPO antibodies positive in ~80%

— Recovery phase of subacute, postpartum, or silent thyroiditis

— Post-RAI ablation, partial thyroidectomy, neck radiation

— Drugs: lithium, amiodarone, interferon-α, tyrosine kinase inhibitors, immune checkpoint inhibitors

— Inadequate levothyroxine dosing in known hypothyroidism

— Nonspecific fatigue, weight gain, cold intolerance, constipation, dry skin, menstrual irregularity, mild depression

— New hyperlipidemia (especially LDL elevation disproportionate to diet)

— Unexplained bradycardia, diastolic hypertension, or pericardial effusion

— Infertility, recurrent miscarriage, ovulatory dysfunction

— Goiter or family history of autoimmune thyroid disease

— However, case-finding is widely accepted in symptomatic patients, women >50–60, autoimmune disease, prior thyroid disease/surgery, amiodarone/lithium users, and infertility workup

— Up to 1/3 normalize spontaneously, especially if TSH <7 and TPO-negative

Board pearl: Before labeling a patient with subclinical hypothyroidism, repeat TSH (with free T4 and TPO) in 6–8 weeks to confirm — a single mildly elevated TSH is often transient (recent illness, lab variability, diurnal variation, biotin interference).

Definition: Elevated TSH with normal free T4 — a biochemical, not clinical, diagnosis

Epidemiology: Prevalence 4–10% of US adults; rises to 15–20% in women >60

Etiology spectrum:

When to suspect (Step 3 ambulatory triggers):

USPSTF stance: Insufficient evidence (I statement) to screen asymptomatic nonpregnant adults

Natural history: ~2–5% per year progress to overt hypothyroidism; higher risk with TSH >10, positive TPO, female sex, age, goiter

Presentation Patterns and Key History

— Many patients are incidentally diagnosed on screening labs ordered for fatigue, lipid panel, or pre-op evaluation

— Constitutional: fatigue, weakness, weight gain (usually <5–10 lb), cold intolerance

— Neuropsychiatric: depressed mood, slowed cognition, poor concentration, sleep changes

— Dermatologic: dry skin, hair thinning, brittle nails

— GI: constipation, bloating

— Reproductive: menorrhagia, oligomenorrhea, infertility, galactorrhea (TRH-driven prolactin rise)

— Musculoskeletal: myalgias, arthralgias, cramps

— Prior thyroid disease, surgery, radioiodine, neck irradiation (lymphoma, H&N cancer)

— Medications: amiodarone, lithium, interferon, checkpoint inhibitors, TKIs (sunitinib), carbamazepine, phenytoin

— Iodine exposure: contrast within 6 weeks, kelp/seaweed supplements

— Biotin supplements (≥5 mg/day) — cause falsely low TSH and falsely high free T4 on immunoassays; hold 48–72 h before retest

— Recent acute illness or hospitalization (nonthyroidal illness/recovery)

— Postpartum status (within 12 months) — postpartum thyroiditis

— Family history: Hashimoto, Graves, T1DM, premature ovarian insufficiency

— Symptomatic + TSH 7–9.9 → consider trial of levothyroxine, especially if <70 yo

— Asymptomatic + TSH <7 → repeat in 6 months, observe

— Positive TPO antibodies → higher progression risk, lowers threshold to treat

Step 3 management: When a patient on stable levothyroxine reports new fatigue with a slightly elevated TSH, before increasing dose, review adherence, timing (empty stomach, 30–60 min before food/coffee), and interfering substances — calcium, iron, PPIs, bile acid sequestrants, soy, and high-fiber meals all impair absorption and produce a falsely "undertreated" picture.

The diagnostic paradox: "Subclinical" is a misnomer — up to 30% report symptoms, but symptoms correlate poorly with TSH level

Symptom clusters to ask about:

Targeted history (Step 3 ambulatory workflow):

Symptom-to-decision linkage:

Physical Exam Findings (and Hemodynamic Assessment when relevant)

— Mild bradycardia (HR 50s–60s)

— Diastolic hypertension from increased systemic vascular resistance

— Low-normal temperature

— Weight modestly elevated or stable

— Inspect with neck extended, swallow water — observe symmetric rise

— Palpate from behind; assess size, symmetry, consistency, nodules, tenderness

— Hashimoto: diffusely enlarged, firm/rubbery, "bosselated" or pebbly surface, nontender

— Subacute (de Quervain) thyroiditis: exquisitely tender, recent viral illness — explains transient elevated TSH in recovery phase

— Postpartum thyroiditis: small, painless, firm goiter

— Atrophic Hashimoto: gland may be small or impalpable

— Dry, coarse skin; cool extremities

— Diffuse hair thinning; loss of lateral third of eyebrows (Queen Anne's sign) — usually overt

— Brittle nails, periorbital puffiness (rare in subclinical)

— Delayed relaxation phase of deep tendon reflexes ("hung-up" reflexes) — classic but uncommon in subclinical

— Mild proximal weakness, carpal tunnel signs (Tinel/Phalen)

— Auscultate for bradycardia, distant heart sounds (rare pericardial effusion if severe)

— Check BP in both arms; subclinical hypothyroidism is associated with endothelial dysfunction and elevated LDL

Key distinction: A tender, painful thyroid with elevated TSH points to recovery phase of subacute/silent thyroiditis (self-limited) — do NOT start levothyroxine reflexively; repeat labs in 4–8 weeks because most normalize spontaneously. Treating transient thyroiditis with chronic LT4 leads to iatrogenic hyperthyroidism and missed diagnosis.

General principle: Most patients with subclinical hypothyroidism have a normal exam — findings are usually subtle and overlap with euthyroid aging

Vital signs:

Thyroid exam (essential and often skipped):

Skin/hair/nails:

Neuro/MSK:

Cardiovascular:

Look for associated autoimmune disease: vitiligo, alopecia areata, pretibial findings (Graves history), goiter, type 1 diabetes injection sites

Diagnostic Workup — Initial Labs

— Repeat TSH + free T4 in 6–8 weeks (or 2–3 months) before labeling

— Rationale: TSH has diurnal variation (highest at night/early morning), pulsatile secretion, and rises transiently after nonthyroidal illness

— Up to 40% of mildly elevated TSH values normalize on repeat

— TSH ↑, free T4 normal → subclinical hypothyroidism

— TSH ↑, free T4 ↓ → overt hypothyroidism (treat)

— TSH ↓ or normal, free T4 ↓ → central (secondary) hypothyroidism — get pituitary MRI and full pituitary panel; do NOT replace levothyroxine before assessing/treating adrenal axis

— TSH ↑, free T4 ↑ → TSH-secreting adenoma or thyroid hormone resistance (rare)

— Upper limit of normal TSH ≈ 4.5 mIU/L in most US labs

— Age-adjusted upper limits: healthy adults >70–80 may have TSH up to 6–7 without disease — avoid overtreating

— Trimester-specific ranges in pregnancy (see chunk 10)

— Anti-TPO antibodies — positive in ~80% of Hashimoto; predicts progression to overt disease (~4%/year vs ~2%/year if negative)

— Anti-thyroglobulin antibodies — adjunctive

— CBC (macrocytic anemia, associated B12 deficiency / pernicious anemia)

— Comprehensive metabolic panel, lipid panel (LDL often elevated)

— Consider HbA1c if T1DM risk; celiac serologies if symptomatic

— Biotin ≥5 mg/day → falsely low TSH, falsely high free T4 (immunoassay interference); hold 48–72 h

— Heterophile antibodies → falsely elevated TSH

— Nonthyroidal illness (sick euthyroid): TSH may transiently rise into 5–20 range during recovery — avoid testing in hospitalized/recently ill patients unless essential

Board pearl: A single TSH between 4.5 and 7 with normal free T4 in an asymptomatic older adult is most likely a lab/biologic transient — repeat in 2–3 months before any intervention.

Step 1 — Confirm the abnormality:

Interpretation framework:

Reference range nuances:

Step 2 — Etiology workup once confirmed:

Pitfalls:

Diagnostic Workup — Advanced or Confirmatory Studies

— Indications: palpable nodule, asymmetric or rapidly enlarging goiter, compressive symptoms (dysphagia, hoarseness), suspicious lymphadenopathy

— Hashimoto pattern: heterogeneous, hypoechoic, micronodular gland with increased vascularity

— Not indicated to "confirm" subclinical hypothyroidism — labs alone suffice

— If nodule ≥1 cm or ≥1.5 cm depending on sonographic features (ACR TI-RADS) → FNA

— Rarely needed in subclinical hypothyroidism

— Useful only if hyperthyroid phase suspected (silent/postpartum/subacute thyroiditis show low uptake) vs Graves (high diffuse uptake)

— MRI brain/pituitary with contrast

— 8 AM cortisol, ACTH, prolactin, LH/FSH, testosterone or estradiol, IGF-1

— Visual field testing if mass effect suspected

— Always assess and treat adrenal insufficiency first before levothyroxine → otherwise can precipitate adrenal crisis

— Baseline rate, QT, ischemic changes

— Levothyroxine can unmask angina or precipitate AF in older adults with CAD

— Treatment of subclinical hypothyroidism (especially TSH ≥10) may lower LDL ~10–20 mg/dL

— Incorporate into ASCVD risk discussion

— Vitamin B12 (pernicious anemia), tTG-IgA (celiac), morning cortisol if symptomatic for Addison, T1DM screening in symptomatic patients

— Down syndrome, Turner syndrome — annual TSH screening recommended lifelong

Step 3 management: In a patient with newly recognized central hypothyroidism (low/normal TSH, low free T4), the order of operations is: (1) confirm with repeat labs, (2) pituitary MRI, (3) assess cortisol axis, (4) replace glucocorticoid if deficient, (5) THEN start levothyroxine. Reversing this order risks adrenal crisis.

Thyroid ultrasound — when indicated, not routine:

Radioactive iodine uptake (RAIU) and scan:

Pituitary workup (if central hypothyroidism suspected):

ECG (if symptomatic or before initiating LT4 in elderly):

Lipid panel and cardiovascular risk recalculation:

Additional autoimmune screening (if clinically indicated):

Genetic considerations:

Risk Stratification and Treatment Decision Logic

— TSH ≥10 mIU/L on repeat testing (regardless of symptoms, with caveats for very elderly)

— Pregnancy or actively trying to conceive with TSH above trimester-specific upper limit

— Overt symptoms attributable to hypothyroidism with confirmed elevated TSH

— Goiter with compressive symptoms

— Infertility workup with elevated TSH (target <2.5)

— Age <65–70: consider trial if symptomatic, TPO-positive, TSH 7–9.9, dyslipidemia, or progressive rise

— Age ≥70–80: generally do NOT treat TSH <10 — TRUST trial and meta-analyses show no symptomatic, QoL, or cardiovascular benefit; increased risk of AF, osteoporosis, falls

— Octogenarians with TSH 4.5–6.9 may represent normal aging — observe

— Document baseline symptoms (validated scale or specific complaints)

— Treat for 3–6 months to target TSH 1–3

— Reassess symptoms — if no improvement, taper off rather than continue indefinitely

— Avoid the trap of lifelong therapy for unproven benefit

— TSH 4.5–6.9, asymptomatic, TPO-negative, age >65

— Recovery phase of thyroiditis (transient)

— Nonthyroidal illness

— TSH ≥10 associated with increased CHD events and heart failure, especially age <65

— Treatment likely reduces events in younger adults; benefit unclear in elderly

Board pearl: The single most testable threshold is TSH ≥10 → treat. The single most testable "do not treat" is asymptomatic adult >70–80 with TSH 4.5–9.9 → observe with repeat labs every 6–12 months.

The central Step 3 question: Treat or observe? Decision integrates TSH magnitude, age, symptoms, antibodies, comorbidities, and pregnancy status.

Universal treatment indications (treat virtually all):

Selective treatment (TSH 4.5–9.9, "gray zone"):

Treatment trial framework if treating gray zone:

Against treatment:

Cardiovascular risk consideration:

Pharmacotherapy — Levothyroxine Initiation and Dosing

— Long half-life (~7 days) allows once-daily dosing and stable levels

— Generic acceptable but stay with one manufacturer — bioequivalence variation can shift TSH

— Healthy adult <60, no CAD: 25–50 mcg/day

— Age >60 or known CAD: 12.5–25 mcg/day, titrate slowly

— Overt hypothyroidism replacement (for contrast): ~1.6 mcg/kg/day full weight-based dose

— Goal: TSH in lower half of normal range (1–2.5 mIU/L) for most adults; upper half (3–5) acceptable in elderly to avoid overtreatment

— Take 30–60 min before breakfast with water on empty stomach, OR at bedtime ≥3 h after last meal

— Separate from calcium, iron, magnesium, aluminum antacids, PPIs, bile acid sequestrants, sucralfate by ≥4 hours

— Avoid coffee, soy, high-fiber within 1 hour

— Consistency matters more than the specific time

— Recheck TSH 6–8 weeks after initiation or dose change (one half-life × 4–5)

— Titrate in 12.5–25 mcg increments

— Once stable: TSH every 6–12 months

— Not recommended as first-line; no superiority over LT4 monotherapy in trials

— Short half-life → supraphysiologic peaks

— May be considered in select patients with persistent symptoms despite normalized TSH on LT4, but this is specialist territory

— Estrogen (OCPs, HRT, pregnancy) ↑ TBG → ↑ LT4 requirement

— Androgens, glucocorticoids ↓ requirement

— Rifampin, phenytoin, carbamazepine ↑ clearance → ↑ requirement

Step 3 management: If TSH remains elevated despite appropriate LT4 dose, verify adherence and administration timing before escalating dose. The most common cause of "refractory" hypothyroidism is taking LT4 with coffee, calcium, or food.

Drug of choice: levothyroxine (LT4) — synthetic T4, converted peripherally to T3

Starting dose in subclinical hypothyroidism (lower than overt):

Administration counseling (critical for absorption):

Monitoring cadence:

Liothyronine (T3) / desiccated thyroid:

Drug interactions affecting LT4 requirement:

Expanded Pharmacology — Adjustment, Pitfalls, and Special Scenarios

— Weight change >10%: recheck TSH and adjust

— New PPI, calcium, iron, estrogen: recheck TSH in 6–8 weeks

— Starting bile acid sequestrant or sevelamer: separate by 4+ hours; expect dose increase

— Malabsorption (celiac, bariatric surgery, IBD): may need liquid LT4 or higher dose

— Bariatric surgery: switch to liquid or soft-gel LT4 formulations

— Atrial fibrillation — risk ↑ 2–3× in iatrogenic hyperthyroidism, especially older adults

— Accelerated bone loss / osteoporotic fractures, particularly postmenopausal women

— Tachycardia, palpitations, tremor, heat intolerance, weight loss, anxiety, insomnia

— Always taper down if TSH suppressed in subclinical patient — many can stop entirely

— Verify adherence (most common); check pill count, refill history

— Confirm correct timing relative to food/drugs

— Check for new interfering meds

— Consider malabsorption workup if unexplained

— Reserved for persistently symptomatic patients with normalized TSH on monotherapy

— Limited evidence; not standard of care

— Avoid in pregnancy, CAD, arrhythmia, elderly

— Tablets (standard), soft-gel capsules (Tirosint), oral liquid — better absorption with PPI use, gastritis, bariatric surgery, or coffee co-administration

— More expensive; reserve for documented absorption issues

— In gray-zone patients without clear indication who started a "trial," consider withdrawal after 6 months if no symptomatic benefit

— Recheck TSH 6–8 weeks after stopping; many remain euthyroid

CCS pearl: For a stable subclinical hypothyroid patient newly started on omeprazole, calcium carbonate, or ferrous sulfate, advance the simulated clock and order TSH in 6–8 weeks; anticipate the need for a modest LT4 dose increase or separation of administration times.

Dose adjustment scenarios:

Overtreatment red flags (TSH <0.5):

Undertreatment signs (TSH persistently >goal):

Combination T4/T3 therapy:

Levothyroxine in special formulations:

Stopping therapy:

Special Populations — Elderly and Renal/Hepatic Impairment

— TSH normally rises with age; upper reference may be 6–7 in healthy octogenarians

— TRUST trial (NEJM 2017): LT4 in adults ≥65 with TSH 4.6–19.9 (mostly <10) showed no improvement in symptoms or QoL

— IEMO 80+ trial: No benefit in adults ≥80

— Risks of treatment in elderly: AF, osteoporotic fracture, angina, anxiety, polypharmacy

— Recommendation: Do NOT treat TSH <10 in asymptomatic adults ≥70–80; observe annually

— If treating (TSH ≥10 or strongly symptomatic): start 12.5–25 mcg, titrate slowly every 6–8 weeks, target TSH 3–6 mIU/L rather than 1–2

— LT4 increases myocardial O2 demand → can precipitate angina, MI, arrhythmia

— Start 12.5–25 mcg/day, increase by 12.5–25 mcg every 4–6 weeks

— Stress test or cardiology input if symptoms emerge

— Goal TSH in upper-normal range

— Subclinical hypothyroidism (TSH ≥10) associated with worse outcomes

— Cautious replacement may improve LV function; start low

— TSH may be falsely elevated in advanced CKD due to altered clearance/HPT axis

— No dose adjustment of LT4 needed by renal function

— Avoid overtreatment — accelerates bone loss in dialysis patients

— No specific dose adjustment; LT4 metabolism preserved

— Cirrhosis can lower TBG and alter free T4 measurement — interpret in context

— Review for interacting drugs (calcium, iron, PPI, bisphosphonates, sevelamer)

— Deprescribing review — elderly initiated on LT4 for "subclinical" disease decades ago often warrant a withdrawal trial

Key distinction: In an 82-year-old with TSH 6.2, fatigue, and normal free T4 — the answer is reassurance and recheck in 6 months, NOT levothyroxine. Treating risks AF and fractures without symptomatic benefit.

Older adults (≥65, especially ≥80):

Coronary artery disease:

Heart failure:

Renal impairment / dialysis:

Hepatic impairment:

Polypharmacy considerations in elderly:

Special Populations — Pregnancy, Preconception, and Pediatrics

— Fetal brain development depends on maternal T4 in the first trimester (fetal thyroid not functional until ~12 weeks)

— Untreated maternal subclinical hypothyroidism associated with miscarriage, preterm birth, gestational HTN, low birth weight, possibly impaired neurodevelopment

— Use pregnancy- and assay-specific reference ranges if available

— Otherwise: T1 upper limit ~4.0 mIU/L (not 2.5 — older threshold revised)

— T2/T3 upper limit ~4.0–4.5

— Lower limits also shift downward in T1 due to hCG cross-reactivity at TSH receptor

— TSH > trimester-specific upper limit + TPO-positive → treat with LT4

— TSH >10 regardless of antibody status → treat

— TSH 2.5–4 + TPO-positive → consider treatment, especially with prior miscarriage/infertility

— TSH 2.5–4 + TPO-negative → generally observe

— Newly diagnosed: LT4 ~1.0–1.2 mcg/kg/day, target TSH <2.5

— Pre-existing hypothyroidism: increase dose by ~25–30% as soon as pregnancy confirmed (e.g., 2 extra tablets per week)

— Recheck TSH every 4 weeks through midpregnancy, then once in T3

— Postpartum: return to pre-pregnancy dose, recheck in 6 weeks

— Target TSH <2.5 before conception in women trying to conceive with known thyroid disease or infertility

— Occurs in 5–10% within 12 months postpartum

— Triphasic (hyper → hypo → euthyroid) or monophasic

— Subclinical or overt hypo phase: treat symptomatic patients with LT4 for 6–12 months, then taper to assess permanence (~20% persist)

— Persistent TSH >10 or symptomatic → treat

— Mild elevations (5–10) in asymptomatic euthyroid children with normal growth → often observe; many normalize

Board pearl: A pregnant patient on stable LT4 needs her dose increased by ~25–30% at first positive pregnancy test and TSH rechecked every 4 weeks. The "two extra pills per week" rule is the highest-yield management pearl in this topic.

Pregnancy — high-stakes, frequently tested:

Trimester-specific TSH upper limits (ATA 2017):

Treatment thresholds in pregnancy:

Dosing in pregnancy:

Preconception (infertility/ART):

Postpartum thyroiditis:

Pediatrics:

Complications and Adverse Outcomes

— ~2–5% per year overall

— TPO-positive: ~4%/year

— TSH >10: highest progression risk

— Cumulative 10-year progression up to 30–50% in high-risk subgroups

— Dyslipidemia: ↑ LDL, ↑ total cholesterol (more pronounced when TSH ≥10)

— Endothelial dysfunction, ↑ arterial stiffness

— Diastolic dysfunction, impaired LV relaxation

— Increased risk of coronary heart disease events and HF, especially in adults <65 with TSH ≥10

— Possible association with stroke in younger patients

— Modest BP elevation (diastolic)

— Infertility, anovulation, luteal phase defects

— Recurrent pregnancy loss, especially with positive TPO

— Preterm delivery, low birth weight

— Possible impact on offspring neurocognition

— Mild executive dysfunction, depression — controversial; benefits of treatment inconsistent except when TSH ≥10

— Mild proximal myopathy, ↑ CK

— Carpal tunnel syndrome

— Macrocytic anemia

— Hyponatremia (more typical of overt)

— Atrial fibrillation — relative risk ~2–3× when TSH suppressed

— Osteoporosis and fragility fractures — postmenopausal women at highest risk

— Anxiety, palpitations, insomnia, weight loss

— Precipitation of angina/MI in CAD

— Severe end-stage overt hypothyroidism — hypothermia, hypotension, altered mental status, hyponatremia, hypoventilation

— Triggered by infection, cold exposure, sedatives, surgery

— Subclinical patients generally not at risk unless they progress and remain untreated

Step 3 management: A postmenopausal woman on LT4 with TSH 0.2 and a new DEXA T-score of −2.7 → reduce LT4 dose to bring TSH into normal range, start calcium/vitamin D, and consider bisphosphonate per FRAX. Iatrogenic subclinical hyperthyroidism is a modifiable osteoporosis risk factor.

Progression to overt hypothyroidism:

Cardiovascular consequences:

Reproductive complications:

Cognitive/mood:

Musculoskeletal:

Hematologic/metabolic:

Iatrogenic complications of overtreatment:

Myxedema coma (rare in subclinical):

When to Escalate Care — Consultation and Referral

— Pregnancy or planning pregnancy with thyroid dysfunction, infertility, or recurrent loss

— Pediatric patients with persistent abnormalities

— Central hypothyroidism (low/normal TSH + low free T4) — needs pituitary workup

— Discordant labs (TSH and free T4 not fitting expected pattern) — assay interference, TSH-secreting adenoma, thyroid hormone resistance

— Unstable disease despite appropriate LT4 dosing and adherence

— Suspected secondary causes — amiodarone-induced, post-radiation, immune checkpoint inhibitor thyroiditis

— Thyroid nodules ≥1–1.5 cm or suspicious sonographic features → FNA

— Patient considering combination T4/T3 therapy

— Severe symptoms not responding to normalized TSH

— Known CAD or HF with new LT4 initiation

— New AF in patient on LT4

— Worsening angina after dose change

— Pregnant patients with overt hypothyroidism, TSH >10, or unstable disease

— Routine subclinical in pregnancy can be managed by OB/PCP with endocrine input

— Suspected myxedema coma in a patient who has progressed: ICU admission, IV LT4 ± T3, stress-dose hydrocortisone (before thyroid hormone), passive rewarming, treat precipitant — emergency

— Suspected adrenal crisis when central hypothyroidism replacement was started without glucocorticoid coverage → IV hydrocortisone immediately

— Compressive goiter, dominant nodule with suspicious FNA, retrosternal extension

CCS pearl: In any patient with suspected central hypothyroidism on a CCS case, the order set is stat 8 AM cortisol, ACTH, prolactin, LH/FSH, IGF-1, MRI pituitary with contrast, endocrine consult, hold levothyroxine until adrenal axis assessed. Starting LT4 before glucocorticoid in adrenal insufficiency precipitates crisis — a classic CCS trap.

Most subclinical hypothyroidism is managed in primary care. Referral to endocrinology is indicated for:

Endocrinology referral:

Cardiology co-management:

OB referral:

Inpatient/urgent escalation (rare for subclinical):

Surgical referral:

Key Differentials — Same-Category (Thyroid) Causes of Elevated TSH

— Most common cause; TPO-positive in ~80%

— Diffuse firm/rubbery goiter or atrophic gland

— Slow, progressive course

— Subacute (de Quervain): post-viral, painful tender goiter, ↑ ESR/CRP; triphasic pattern (hyper → hypo → euthyroid)

— Silent (painless) thyroiditis: similar triphasic course, no pain, ± TPO

— Postpartum thyroiditis: within 12 months of delivery

— Key feature: transient — repeat labs in 4–8 weeks, most normalize; avoid premature LT4

— Amiodarone-induced hypothyroidism (Wolff-Chaikoff persistence) — common; treat with LT4, can continue amiodarone if needed

— Lithium — inhibits thyroid hormone release

— Interferon-α, immune checkpoint inhibitors (pembrolizumab, nivolumab) — can induce thyroiditis with hyper followed by hypo phase

— Tyrosine kinase inhibitors (sunitinib, sorafenib)

— Post-radioiodine ablation, post-thyroidectomy, neck radiation

— Iodine deficiency (rare in US)

— Iodine excess (kelp, contrast, amiodarone) — Wolff-Chaikoff effect

— Established hypothyroidism with elevated TSH on therapy — adherence/timing issues, drug interactions, malabsorption, weight gain

— Riedel thyroiditis (rare), hemochromatosis, amyloidosis — usually present with goiter or hard fixed gland

— Thyroid hormone resistance, TSH receptor mutations — usually identified earlier in life

Key distinction: Hashimoto = persistent, antibody-positive, progresses. Thyroiditis (subacute/silent/postpartum) = transient hypo phase recovering toward euthyroidism — distinguished by clinical context (pain, postpartum status, recent illness) and trajectory on repeat labs. Treating the latter with chronic LT4 is a common error.

Distinguishing causes of an isolated elevated TSH:

Chronic autoimmune (Hashimoto) thyroiditis:

Recovery phase of transient thyroiditis:

Iatrogenic / drug-induced:

Iodine-related:

Inadequate LT4 dosing or absorption:

Infiltrative disease:

Congenital:

Key Differentials — Non-Thyroid Causes and TSH Mimics

— Acute/chronic illness, hospitalization, starvation

— During illness: low T3, low/normal T4, normal/low TSH

— During recovery: TSH transiently rises into 5–20 range, free T4 normal — mimics subclinical hypothyroidism

— Management: do not test thyroid function during acute illness; if abnormal, repeat 6–8 weeks after recovery

— Heterophile antibodies (HAMA) — falsely high TSH; alert lab to use blocking tubes

— Macro-TSH — biologically inactive TSH-IgG complex; high TSH, normal free T4, no symptoms; lifelong abnormality, no treatment

— Anti-streptavidin/anti-ruthenium antibodies in some assays

— Biotin — usually falsely low TSH, high free T4 (mimics hyperthyroidism), but assay-dependent; hold supplement 48–72 h

— Primary adrenal failure can elevate TSH (resolves with glucocorticoid replacement) — always consider in concurrent fatigue, hypotension, hyperpigmentation, hyponatremia

— TSH-secreting adenoma — rare, TSH and free T4 both elevated

— Resistance to thyroid hormone — TSH and free T4 both elevated, no clinical hyperthyroidism

— Dopamine antagonists (metoclopramide) — modest TSH elevation

— Recovery from dopamine, glucocorticoid, octreotide withdrawal

— Mild TSH elevation (TSH 4.5–7) common in obesity; reverses with weight loss

— Generally do NOT treat with LT4 for weight loss — ineffective and unsafe

— Depression, OSA, anemia, vitamin D deficiency, fibromyalgia, chronic fatigue syndrome, perimenopause

— These should be considered before attributing nonspecific fatigue to mild TSH elevation

Board pearl: A patient with TSH 8.0, normal free T4, no symptoms, on biotin 10,000 mcg daily for hair, and a recent hospital stay for pneumonia — stop biotin, repeat labs in 6–8 weeks off biotin and post-illness. Do not start levothyroxine reflexively.

Non-thyroidal illness syndrome (sick euthyroid):

Assay interference (false elevations):

Adrenal insufficiency:

Pituitary disorders:

Medications causing elevated TSH without thyroid disease:

Obesity:

Other mimics of "hypothyroid" symptoms with normal thyroid:

Long-Term Plan, Counseling, and Secondary Prevention

— TSH 4.5–6.9, asymptomatic: recheck every 6–12 months

— TSH 7–9.9, asymptomatic, <65: every 6 months ± TPO trend

— Counsel on symptoms warranting earlier recheck: progressive fatigue, weight gain, cold intolerance, bradycardia, constipation

— Encourage cardiovascular risk factor management — lipids, BP, diabetes, smoking, weight

— Pregnancy planning → recheck before conception and at confirmation

— Lifelong therapy typically required if Hashimoto-based

— TSH every 6–12 months once stable; sooner with dose changes, new interacting meds, weight change >10%, pregnancy

— Reinforce adherence and administration timing at every visit — most common cause of instability

— Avoid switching between manufacturers; if switched, recheck TSH in 6–8 weeks

— Carry medication list; counsel on supplement interactions (calcium, iron, biotin)

— Bone health: DEXA per USPSTF in women ≥65; earlier if iatrogenic hyperthyroid history

— Cardiovascular: annual lipids, ASCVD risk discussion

— Patients who started LT4 for vague indications years ago, on doses <50 mcg, with no clear diagnosis → consider stopping with TSH check at 6–8 weeks

— Many will remain euthyroid

— Adequate iodine (typically ensured by iodized salt; avoid kelp megadoses)

— Selenium: insufficient evidence to recommend supplementation

— No specific "thyroid diet"; emphasize Mediterranean pattern for CV risk

— Avoid unregulated "thyroid support" supplements — may contain T3/T4

— Document treatment goal TSH range in the chart

— Update problem list and medication list at every transition

— Communicate dose at discharge from any hospitalization

Step 3 management: At every visit for a patient on LT4, explicitly review timing, food/coffee separation, and concurrent supplements — this single counseling action prevents most cases of "refractory" subclinical hypothyroidism and unnecessary dose escalation.

For patients NOT treated (observation pathway):

For patients ON levothyroxine:

Trial withdrawal consideration:

Lifestyle and self-management counseling:

Care coordination:

Follow-Up, Monitoring Parameters, and Counseling Cadence

• Monitoring schedule summary:
Scenario	TSH check interval
—	—
Initial confirmation	6–8 weeks
After LT4 initiation or dose change	6–8 weeks
Stable on LT4, nonpregnant	Every 6–12 months
Pregnancy (known thyroid disease)	Every 4 weeks until midpregnancy, then once in T3
Observation (untreated subclinical)	Every 6–12 months
New interacting medication	6–8 weeks
Postpartum on LT4	6 weeks after return to pre-pregnancy dose
• What to monitor besides TSH:
— Free T4 if symptoms discordant with TSH, suspected central disease, or pregnancy
— TPO antibodies once at diagnosis (prognostic); not repeated routinely
— Lipid panel annually if elevated baseline
— DEXA per age guidelines; earlier if iatrogenic hyperthyroid episode
— Vitamin D, B12 in autoimmune cluster patients
— Symptom inventory at each visit — if started LT4 for symptoms, reassess at 3–6 months
• Counseling content:
— What subclinical hypothyroidism means — biochemical finding, not necessarily disease
— Natural history: may resolve, persist, or progress
— Rationale for current strategy (treat vs observe)
— Pregnancy implications for women of reproductive age
— Side effects of overtreatment (palpitations, anxiety, bone, AF)
— Medication interactions and administration
— When to call: chest pain, palpitations, new AF, severe fatigue, pregnancy
• Quality measures and value-based care:
— Avoid unnecessary thyroid testing in asymptomatic adults (Choosing Wisely)
— Avoid LT4 initiation in TSH <7 asymptomatic elderly
— Avoid T3/desiccated thyroid as first-line
— Avoid free T3 testing routinely
• Telehealth/portal management:
— Stable LT4 patients are well suited to telehealth — lab review, dose adjustments, counseling
— Reserve in-person visits for new diagnosis, pregnancy, unstable disease
Board pearl: The 6–8 week recheck after any LT4 dose change is the single most testable monitoring interval — derived from LT4's 7-day half-life requiring 4–5 half-lives to reach steady state.

Ethical, Legal, and Patient Safety Considerations

— Gray-zone subclinical hypothyroidism (TSH 4.5–9.9) is the prototypical SDM scenario

— Discuss: uncertain benefit, lifelong commitment if initiated, risk of overtreatment (AF, fracture), small chance of symptom improvement

— Document patient preference and rationale; especially important in older adults where guidelines counsel against treatment

— A single mildly elevated TSH is not a diagnosis — repeat before labeling

— Once "hypothyroidism" enters the problem list, it tends to persist for life and drive unnecessary testing and prescribing

— Periodic deprescribing review, especially in elderly on long-standing low-dose LT4 of unclear origin

— Hospital discharge: ensure LT4 is on the discharge med list at correct dose; medication reconciliation error is a common cause of missed doses or duplicate prescriptions

— Pregnancy confirmation: rapid handoff between PCP, OB, endocrine; ensure dose increase happens promptly

— Surgery/NPO: LT4 can be held 5–7 days without consequence (long half-life); if NPO prolonged, use IV LT4 at ~75% of oral dose

— New PPI, calcium, iron prescription: counsel on separation; flag in EHR

— Never start LT4 in suspected central hypothyroidism before confirming adrenal axis — risk of adrenal crisis (sentinel event)

— Look-alike/sound-alike: levothyroxine vs liothyronine, different doses (mcg not mg)

— Verify dose at every transition — common error to enter "0.05 mg" as "50 mg"

— Pregnant patients on LT4 must NOT skip doses; counsel on backup if vomiting

— Cost: generic LT4 is inexpensive; brand-name and soft-gel formulations may be costly — confirm coverage

— Language-concordant counseling on administration is critical for adherence

Step 3 management: Always cross-check the LT4 dose at every care transition (admission, discharge, surgery, pregnancy, new prescriber) — this is a Joint Commission medication reconciliation focus area and a frequent source of harm.

Informed consent and shared decision-making:

Avoiding overdiagnosis and overtreatment:

Transitions of care — high-risk moments:

Patient safety pearls:

Health literacy and equity:

Ethical case: Elderly patient with mild cognitive impairment, on LT4 of unclear origin for 20 years, now with osteoporosis. Discuss withdrawal trial with patient and surrogate, document shared decision, and recheck TSH at 6–8 weeks.

High-Yield Associations and Rapid-Fire Clinical Facts

Board pearl: If only one cutoff sticks: TSH ≥10 = treat; TSH <10 + asymptomatic elderly = observe; pregnancy = lower threshold + immediate dose bump. These three rules cover ~80% of testable scenarios.

TSH ≥10 → treat (almost always)

TSH 4.5–9.9 + age >70 + asymptomatic → observe, do not treat

TSH 4.5–9.9 + symptomatic + age <65 + TPO-positive → trial of LT4, reassess at 3–6 months

Pregnancy + TSH > trimester upper limit (~4) → treat

TPO-positive doubles annual progression rate (~4%/year vs 2%)

Increase LT4 ~25–30% at first positive pregnancy test in known hypothyroidism

LT4 half-life ~7 days → recheck TSH 6–8 weeks after any change

Goal TSH 1–2.5 in most adults; 3–6 in elderly to avoid overtreatment

Take LT4 30–60 min before food or at bedtime ≥3 h post-meal

Separate from calcium, iron, PPI, sucralfate, bile acid sequestrants by 4 h

Biotin → falsely low TSH, falsely high free T4; hold 48–72 h

Heterophile antibodies → falsely high TSH

Macro-TSH → high TSH, normal free T4, asymptomatic, no treatment

Subacute thyroiditis → painful gland, post-viral, ↑ ESR, low RAIU

Postpartum thyroiditis in 5–10% of women within 12 months; ~20% become permanent

Amiodarone, lithium, interferon-α, immune checkpoint inhibitors, TKIs → induce hypothyroidism

Iatrogenic hyperthyroidism (TSH <0.5) → AF, osteoporosis, fractures

Central hypothyroidism → use free T4, not TSH, to monitor; treat adrenal axis first

TRUST trial → no benefit of LT4 in older adults with mild subclinical hypothyroidism

USPSTF → insufficient evidence to screen general asymptomatic adults

Lipid effect → treatment may lower LDL 10–20 mg/dL when TSH ≥10

Infertility / recurrent miscarriage → target TSH <2.5 preconception

Obesity can cause mild TSH elevation that normalizes with weight loss

Down syndrome, Turner syndrome → screen annually for life

Bariatric surgery → consider liquid/soft-gel LT4 for absorption

Generic-to-brand or manufacturer switch → recheck TSH 6–8 weeks

Hashimoto = most common cause; firm/rubbery diffuse goiter, TPO-positive

Board Question Stem Patterns

— 78-year-old woman, routine labs, TSH 6.8, free T4 normal, no symptoms

— Answer: Reassure, repeat TSH in 6 months. NOT levothyroxine.

— Trap: choosing LT4 because TSH is "abnormal"

— 45-year-old with fatigue, TSH 12.4, free T4 low-normal, TPO positive

— Answer: Start levothyroxine 50 mcg daily, recheck TSH in 6–8 weeks

— 28-year-old on LT4 100 mcg for Hashimoto, positive pregnancy test at 6 weeks

— Answer: Increase LT4 to ~125 mcg (or 2 extra pills/week), recheck TSH in 4 weeks

— Variant: newly diagnosed in pregnancy, TSH 5.2, TPO+ → start LT4

— Patient on stable LT4, started omeprazole or calcium, now TSH rising

— Answer: Counsel on separation by 4 hours; recheck TSH in 6–8 weeks before dose change

— Young woman 4 months postpartum, mild fatigue, TSH 7.2, free T4 normal

— Answer: Repeat labs in 4–8 weeks; most resolve spontaneously

— Patient on high-dose biotin, TSH suppressed and free T4 elevated, asymptomatic

— Answer: Hold biotin 48–72 h, repeat thyroid function tests

— Fatigue, low free T4, low/normal TSH, headaches, visual changes

— Answer: MRI pituitary, 8 AM cortisol, full pituitary panel; treat adrenal axis FIRST, then LT4

— Postmenopausal woman on LT4, TSH 0.1, new palpitations or osteoporosis

— Answer: Reduce LT4 dose, recheck in 6–8 weeks

— Older adult, TSH 6, started on LT4 6 months ago, no symptom improvement

— Answer: Taper off LT4, recheck TSH 6–8 weeks later

— New amiodarone, lithium, or checkpoint inhibitor → rising TSH

— Answer: Continue offending drug if essential, start LT4 if TSH ≥10 or symptomatic

Key distinction: Step 3 stems reward restraint: identifying when NOT to treat is as testable as starting therapy. Default toward observation in older, asymptomatic, mildly elevated TSH.

Pattern 1 — The asymptomatic elderly stem:

Pattern 2 — The TSH ≥10 stem:

Pattern 3 — The pregnancy stem:

Pattern 4 — The absorption/adherence stem:

Pattern 5 — The transient thyroiditis stem:

Pattern 6 — The biotin stem:

Pattern 7 — The central hypothyroidism trap:

Pattern 8 — The iatrogenic hyperthyroidism stem:

Pattern 9 — The TRUST-trial-flavored stem:

Pattern 10 — The drug-induced stem:

One-Line Recap

Treat subclinical hypothyroidism when TSH is ≥10 or when the patient is pregnant, symptomatic and young, infertile, or strongly TPO-positive — observe everyone else, especially asymptomatic older adults, and always confirm with a repeat TSH before labeling.

Board pearl: Subclinical hypothyroidism is a biochemical state, not a disease — your job is to decide whether the biochemistry warrants pharmacologic action, and in most adults <TSH 10 without compelling indications, the evidence-based answer is watchful waiting with structured follow-up.

Threshold trio: TSH ≥10 → treat; TSH 4.5–9.9 → individualize (age, symptoms, TPO, pregnancy); asymptomatic elderly with TSH <10 → observe

Pregnancy is special: trimester-specific cutoffs (~4.0 upper limit), treat above threshold if TPO+, increase pre-existing LT4 by 25–30% at conception, recheck every 4 weeks

Levothyroxine logistics: start low (25–50 mcg, or 12.5–25 in elderly/CAD), take 30–60 min before food, separate from calcium/iron/PPI by 4 hours, recheck TSH at 6–8 weeks after any change, target TSH 1–2.5 (3–6 in elderly)

Avoid the traps: never treat a single mildly elevated TSH without confirmation, never start LT4 in central hypothyroidism before assessing adrenal axis, never miss biotin interference, never overtreat (AF, osteoporosis), and never reflexively treat transient thyroiditis or non-thyroidal illness recovery

Step 3 voice: ambulatory, longitudinal, shared decision-making heavy — the right answer is often "repeat the lab in 6–8 weeks and counsel," not "start levothyroxine"